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Abstract
In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged
cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial
results in recovering damaged cardiac tissue. New progress has shown that the underlying
mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than
on new tissue generation. However, studies have also reported the potential of new endothelial cell
generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or
therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were
isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will
describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+
cells.
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Cardiovascular disease is one of the most serious health challenges worldwide. In the USA,
nearly 80 million people are affected by myocardial infarction (MI), stroke and ischemic
cardiomyopathy each year [1]. Despite advances in surgical and medical treatment, current
therapies are still short of regaining cardiac function. Due to the limited regeneration
capacity of the myocardium, severely damaged cardiac muscle following myocardial injury
such as MI can lead to adverse ventricular remodeling and heart failure. Until recently, there
have been no clinical procedures or medication that has proved to effectively regenerate
damaged myocardium and, thus, new approaches have been desired for a long time. The
recent identification of adult stem or progenitor cells has raised the possibility of
regenerating damaged myocardium, particularly cardiomyocytes and/or vessels. Among
those, bone marrow (BM)-derived stem or progenitor cells have been most widely
investigated [2–4].
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Growing evidence suggests that BM-derived stem cells have a multipotent capacity to
differentiate into nonhematopoietic tissues, such as skeletal myoblasts [5,6], endothelium
[7], cardiomyocytes [8], gut, lung, skin epithelia [9] and neural cells [10]. This plasticity of
BM cells is supported by the detection of donor-derived transplanted BM cells in the heart
[11–13] and brain [14]. Based on these promising preclinical data, various BM or peripheral
blood (PB)-derived mononuclear cells (MNCs), endothelial progenitor cells (EPCs) and
mesenchymal stem cells (MSCs) have been implemented in patients with acute MI or more
chronic forms of heart failure. Earlier clinical studies showed improvement of regional or
global left ventricular function [15–19]; however, later studies reported marginal or no
therapeutic improvement of cardiac function in a similar subset of patients [20–23]. In order
to elucidate these conflicting results, more global multicenter trials are needed. More
importantly, to enhance the therapeutic effects, there should be ongoing efforts to elucidate
the mechanisms of the cell therapy as well as the discovery of new cells with higher
therapeutic potential. The following sections will cover the characteristics and the
therapeutic potential of the most widely used BM-derived stem or progenitor cells and a
recently identified novel angio-vasculogenic cell type, CD31+ cells.
Endothelial progenitor cells
The development of the vascular system is comprised of two processes: vasculogenesis and
angiogenesis [24]. Vasculogenesis involves the in situ formation of blood vessels through
differentiation into endothelial cells (ECs) from angioblasts or progenitor ECs and gives rise
to capillaries [25]; whereas angiogenesis refers to the extension of pre-existing blood vessels
by sprouting or intussusceptions of capillaries through proliferation or migration of ECs.
Historically, angiogenesis was thought to be responsible for neovascularization in both
neonatal and postnatal developmental stages. However, vasculogenesis was believed to
occur only during the embryonic developmental period.
In 1997, Asahara et al. reported the existence of circulating progenitor cells or angioblasts
isolated from human PB (hPB) that not only displayed EC properties but also showed the
potential to differentiate into ECs [26]. These cells were referred to as EPCs. These EPCs
were shown to be incorporated into the vasculature in adult animals and induce new vessel
formation in ischemic tissues [27]. The transplantation of EPCs into ischemic tissues
induced neovascularization and helped regenerate ischemic tissue damage [28]. Although
this novel concept of postnatal vasculogenesis has been widely accepted, the precise
identification of genuine EPCs has been complicated by the lack of specific markers and
phenotype diversity.
Early EPCs
Initially, CD34 or VEGF receptor (VEGFR)-2 was used to isolate circulating EPCs or
putative angioblasts from PB [26,29,30]. As there are no known surface markers for
specifically isolating circulating EPCs, EPCs were identified by short-term culture of
various BM cell fractions in endothelial differentiation media. For example, CD133, which
is displayed on immature hematopoietic stem cells (HSCs), was used for culture derivation
of EPCs [31]. For therapeutic purposes, short-term culture of MNCs was widely used for
deriving EPCs. Whole MNCs were cultured for 4–7 days on vitronectin- or fibronectin-
coated dishes and adherent cells were regarded as EPCs (although these cells are not EPCs
as a whole but EPC-enriched cells) [26–28,32,33]. Typically these cultured cells displayed
endothelial-like characteristics represented by the uptake of acetylated low-density
lipoproteins and the binding of lectins and expression of several EC-specific proteins
(VEGFR-2, Tie2, vascular endothelial [VE]-cadherin, von Willebrand factor, endothelial
nitric oxide synthase and CD146) and showed a low proliferation rate. However, other
studies have raised questions regarding the pure endothelial-like features of these EPCs and
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revealed that they also express monocyte/macrophage markers such as CD45, CD14, CD11b
and CD11c [34–37]. More recently these cells were called circulating angiogenic cells [37]
as these EPCs rarely give rise to ECs in vivo but contribute to vessel formation mainly
through angiogenic effects. Alternative techniques have been used to isolate cells similar to
these EPCs, where whole MNCs were seeded on fibronectin-coated plates. After 2 days,
only nonadherent cells were collected for removal of mature ECs and macrophages, and
subsequently reseeded on fibronectin-coated plates. Colonies were generated after 5–9 days
and named colony-forming unit-Hill or colony-forming unit-ECs [38]. Since these cells
appear to share similar properties with the aforementioned EPCs, collectively they were
called early EPCs.
Late EPCs
Recently, other types of EPCs have been discovered from circulating MNCs, such as
outgrowth ECs [39], late EPCs [29] or endothelial colony-forming cells (ECFCs) as these
cells appear late (typically more than 2 weeks) in the EPC culture conditions. Although the
culture methods are somewhat variable, these cells essentially share common characteristics
in cell morphology (round), proliferation rate (rapid) and surface marker expression (EC
markers only) [36,40]. For culture derivation of ECFCs, PB or cord blood MNCs were
plated on collagen type-1-coated dishes with endothelial growth media-2. After one day,
nonadherent cells were depleted and only adherent cells were cultured in endothelial growth
media-2. Colonies appeared 5–22 days after plating as monolayers of cobblestone-appearing
ECs. ECFCs can form de novo vessels in vitro and have a similar phenotype to cultured ECs
[36,40]. Specifically, ECFCs do not express hematopoietic (CD45) and monocytic (CD14)
markers but express most EC proteins. However, paracrine effects are limited compared
with early EPCs [41]. Their vasculogenic effects were only demonstrated in a Matrigel™
plug assay [41]. Thus, their EC generation capabilities and regenerative effects on
vasculature in ischemic animal models need to be addressed. It is possible that these cells
are primitive circulating ECs or ECs sloughed off from vessels. The difference between
ECFCs and mature ECs also remains to be determined. For clinical applications, the
advantages and disadvantages are similar to other cultured cells such as MSCs.
Hematopoietic stem cells
Hematopoietic stem cells have the capacity for self-renewal and give rise to every kind of
blood cell [42]. HSCs are one of the best characterized stem cells and have been used for the
treatment of hematologic disease patients for more than three decades. The transplantation
of a single HSC can constitute all hematopoietic cells in an organism and fulfill every stem
cell function. Due to their multipotency, reported in earlier studies [43], HSCs were used to
regenerate damaged myocardium [8]. These studies have shown that HSCs could generate
new cardiomyocytes, ECs and smooth muscle cells and improve post-MI cardiac function.
Another versatile capacity of HSCs has been reported with side population cells, which
expel Hoechst dye [44]. The differentiation potentials of these cells into cardiomyocytes,
ECs and vascular smooth muscle cells were also demonstrated in a MI model [7,8].
However, other studies have argued that HSCs represented by lineage-negative, sca1-
positive and c-kit-positive cells do not transdifferentiate into any cardiovascular cells in the
infarcted heart after HSC transplantation [45,46]. These studies were performed in murine
HSCs and no such experiments were conducted with specific human HSCs other than
CD34+ cells and CD133+ cells that are enriched with human HSCs and EPCs. Studies using
human CD34+ cells [47–50] or CD133+ cells [51–53] have been reported to improve post-
MI cardiac function; however, the therapeutic mechanism turned out to be from
nontransdifferentiation effects. As CD34+ cells or CD133+ cells are present in low numbers
in circulation, the use of mobilizing cytokines such as granulocyte-colony stimulating factor
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(G-CSF) for obtaining a large number of cells needed for clinical use incurs high costs and
risk to patients.
Mesenchymal stem cells
Mesenchymal stem cells need cell culture for isolation and can be derived from a variety of
tissues including BM [54], adipose tissue [55], amniotic fluid [56], cord [57] and umbilical
cord blood [58]. They possess self-renewing potential and differentiation capacity to turn
into osteoblasts, chondrocytes and adipocytes. Earlier studies have shown that MSCs can be
differentiated into cardiomyocytes in vitro [59]. However, differentiation of MSCs into ECs
has not been clearly demonstrated. Several groups reported that MSC implantation into
infarcted hearts decreased fibrosis, myocardial scarring and improved myocardial
regeneration [60–62]. Although earlier studies claimed the mechanism to be myogenesis,
follow-up studies have revealed paracrine effects as a main mechanism underlying
therapeutic effects [63]. Also, another group demonstrated that in a model of murine
hindlimb ischemia, MSC transplantation enhanced tissue repair via secretion of multiple
cytokines including VEGF, basic FGF and PlGF rather than incorporation of MSCs into new
or remodeling tissues [64,65]. To improve the survival rate of injected MSCs in the infarcted
myocardium, genetically modified MSCs (in which heme oxygenase-1 [66] or Akt [67] were
overexpressed) were used and were shown to enhance therapeutic efficacy. [62,68]. Clinical
trials using MSCs for treating acute MI have shown them to be safe, reduce adverse
remodeling and augment myocardial function [16,60,69].
The advantage of MSCs for clinical application lies in the ease of acquisition, isolation and
high expansion capability in culture. One interesting characteristic of MSCs is their low
immunogenicity, which owes itself to a lack of expression of MHC class II. Studies reported
that MSCs have immunomodulatory properties that modulate the function of T cells [70,71].
MSCs are known to induce immune tolerance in allogeneic stem cell transplantations
[72,73]. However, the long-term safety of MSC treatment still needs to be monitored due to
the use of animal serum, allogeneic cell use, the variable quality resulting from long-term
culture expansion and potential tumor formation. Studies have shown that mouse BM-MSCs
can transform after long-term culture and induce tumors in mice [74–76].
Therapeutic effects of adult stem/progenitor EPCs, HSCs & MSCs are
mainly mediated by nontransdifferentiation effects
Despite the fact that stem or progenitor cells have emerged as a promising therapeutic
modality, there have been several controversies regarding therapeutic mechanisms for
ischemic diseases. In particular, the plasticity or true tissue generation capacity
(transdifferentiation into cardiomyocytes, smooth muscle cells and ECs) of BM-derived
cells has been widely debated [45,46,77]. Although therapeutic effects are observed, the
occurrence of vasculogenesis and exogenous myogenesis in damaged tissues are very low.
Later studies more clearly suggested that the paracrine mechanism could be a major
mechanism to mediate therapeutic effects in cardiovascular diseases. BM cells release
cytokines such as VEGF, MCP-1, FGF-2, angiopoetin-1 and Wnt [78–80]. MSCs secrete
VEGF, FGF-2, PlGF and MCP-1 [65,81] and cultured early EPCs secrete HGF, VEGF and
G-CSF [35,74]. One recent study reported an important role of Wnt signaling in mediating
angiogenic effects of human fetal CD133+ cells on ischemic wounds [80]. These growth
factors promote angiogenesis or cardiomyogenesis, protect against tissue apoptosis or
necrosis and induce endogenous resident stem cell migration and proliferation through a
paracrine response [63,65,74,80–82]. Additionally, it is now known that these humoral
effects are not only attributed to implanted cells, but also to host tissues that had received
cell therapy [74,83]. However, the evidence of paracrine effects derived from late EPCs or
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ECFCs is not clearly reported. Other studies have shown that fusion can be a mechanism for
transdifferentiation [84,85]. Although some studies emphasized an important role of fusion
for transdifferentiation [86,87], other studies have shown that fusion is only partly or
minimally responsible for the phenotypic changes of stem cells [81].
Role of CD31 in vascular biology
CD31
Platelet endothelial cell adhesion molecule (PECAM)-1, also known as CD31, is a 130-kDa
molecular weight surface protein that belongs to the immunoglobulin superfamily and
consists of six extracellular immunoglobulin folds (Figure 1). In its cytoplasmic domain,
there are two immunoreceptor tyrosine inhibitory motifs for interactions with signaling
molecules. CD31 is expressed on the cell surface of ECs and hematopoietic cells such as
monocytes, platelets, neutrophils, natural killer cells, megakaryocytes and some T cells.
Platelet endothelial cell adhesion molecule-1 mediates homotypic adhesion between
adjacent ECs as well as between ECs and leukocytes [88,89]. A role for PECAM-1 in
migration through ECs has also been reported for neutrophils and monocytes [90], and
subsequently for numerous other cell types including natural killer cells [91], hematopoietic
progenitor cells (HPCs) [92] and certain subsets of lymphocytes.
Role of CD31 in cell survival & angiogenesis
Cell–cell and cell–extracellular matrix interactions have been shown to play pivotal roles in
coordinating EC proliferation and apoptosis required for proper blood vessel formation and
regression. There is growing evidence that CD31 could transduce signals that suppress cell
death. It has been proposed that homophilic interactions of CD31 between ECs and
monocytes decreases apoptotic EC death [93]. This finding suggests that CD31 homophilic
interactions result in the transmission of prosurvival signals. In addition, CD31 engagement
has been reported to induce Akt phosphorylation. PECAM-1 itself has also been involved
during EC apoptosis by two pathways: a metalloproteinase-dependent cleavage and a
caspase-mediated cleavage of the cytoplasmic tail [94].
Given its abundant expression in ECs, CD31 has been shown to be involved in the initial
stabilization and formation of cell–cell contacts at lateral junctions of ECs, the maintenance
of a vascular permeability barrier, modulation of cell migration, transendothelial migration
of monocytes and neutrophils and formation of blood vessels in angiogenesis [88,90,95,96].
Additionally, CD31 was found to form a functional complex with cadherin 5, β-catenin, and
F-actin to control EC tube formation [97]. More recent data showed the involvement of
CD31 in the adhesion/signaling events necessary for the migration of ECs and subsequent
tube formation during angiogenesis, independent of VE-cadherin [98].
Novel role of CD31-expressing MNCs in circulation
Since the major mechanisms underlying therapeutic effects for BM-derived stem or
progenitor cells were shown to be humoral effects [63,65,99,100], identifying such cells
could lead to the development of next generation cell therapy. Therefore, we explored
whether or not we could isolate cells enriched with humoral activities from BM and/or PB.
At the same time, we wanted to employ a surface marker to isolate these cells. By avoiding
cell culture, direct isolation using a surface marker can circumvent deleterious effects
associated with the use of animal serum and extra costs related to cell cultivation. Since
CD31 is a well-known EC marker, we hypothesized that CD31+ cells may include cells
enriched with vessel-forming activities.
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Angiogenic features of CD31+ cells
To evaluate the characteristics of CD31+ cells in comparison to CD31− cells, we performed
genome-wide gene expression analyses [101,102]; gene set enrichment analysis and
hierarchical cluster analysis with mouse BM (mBM), human BM (hBM), and hPB showed
that angiogenic genes were globally upregualted in CD31+ cells compared with CD31− cells
(Figure 2). The higher expression of angiogenic genes in the CD31+ cells was confirmed by
real-time PCR [101,102]. The angiogenic genes were significantly enriched in the CD31+
cells compared with the corresponding CD31− cells. mBM-CD31+ cells expressed very high
levels of angiopoietin-1 (Angpt1) and Gata2 compared with the CD31− cells, whereas hBM-
CD31+ cells expressed higher levels of heparin-binding EGF-like growth factor (HBEGF)
and IL-8 than hBM-CD31− cells. Angpt1 is a well-known angiogenic growth factor
[103,104] and Gata2 is a transcription factor, which, when activated, increases angiogenesis
[105]. HBEGF is involved in the recruitment of vascular smooth muscle cells [106] and IL-8
is a macrophage-derived mediator of angiogenesis [107]. Neuropilin-1 (NRP1) is the most
highly expressed angiogenic gene in hPB-CD31+ cells compared with hPB-CD31− cells.
NRP1 is required for vascular development and mediates VEGF-dependent angiogenesis
[108].
Vasculogenic effects of CD31
One major focus of our research has been to determine whether any hematopoietic cells
contribute to true EC generation and determine the identity of such cells. Studies from other
investigators and ours have provided strong evidence that there is still quite a reasonable
possibility that certain BM-derived cell populations can give rise to ECs [8,29,109].
However, other studies have strongly argued against these phenomena [46,77,110].
Representative studies that refuted EC generation by hematopoietic cells used MI models
[45,46] to prove the vasculogenic effects. However, an MI model allows very minimal
engraftment of any cells, not only BM-derived cells. Studies have shown that the
engraftment rate of embryonic stem cells differentiated into cardiomyogenic lineages or
cardiac stem or progenitor cells are also very minimal in a MI model [111–113]. The
constant motion of the heart, ongoing inflammation in acute stages of infarction, and little
oxygen and nutrients in the ischemic heart tissue appear to be too harsh for transplanted cells
to engraft and survive. Tight junctions between cardiomyocytes could be another hurdle for
engraftment of externally injected cells. Furthermore, most studies are more focused on
cardiomyocyte transdifferentiation from BM cells rather than ECs. Thus we understood that
the counter evidence for transdifferentiation of BM cells into ECs might have been
overemphasized. We hypothesized that, if appropriate BM-derived cells are injected into
more permissive models, they can give rise to ECs. In fact, recent studies have clearly
demonstrated generation of ECs from BM cells in tumor models [114,115]. Together these
studies suggest that the generation of ECs from BM or PB cells may not only depend on the
cell types but also the experimental models or host environment.
The vasculogenic effects of CD31+ cells have been investigated in our recent studies
[101,102]. First, in vitro assays showed that mBM−, hBM− and hPB-CD31+ cells generated
a markedly high number of EPCs under culture, compared with the CD31− cells. Results
from an in vitro EC differentiation assay using hPB-CD31+ cells showed clear expression of
EC-specific markers, such as von Willebrand factor, VEGFR-2, VE-cadherin and CD31, in
CD31+ cells. In these culture experiments, we observed intriguing morphological changes of
the hPB-CD31+ cells (Figure 3). Under endothelial differentiation conditions, hPB-CD31+
cells formed cellular aggregates on day 7, which subsequently underwent tubular structural
changes within the round cell cluster by day 10. Thereafter, these mixed morphologies
shifted to complete linear tubular structures that mimicked in vivo vasculogenesis. These
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tubular structures were positive for lectin and took up acetylated human low-density
lipoprotein, indicating EC characteristics.
Bona fide evidence of vasculogenesis should be confirmed by in vivo animal models. A
mouse model of hindlimb ischemia was used for testing vasculogenic capacity of CD31+
cells [101,102]. As the rate of transdifferentiation of hematopoietic cells into ECs was
reported to be 0–50% [35,46,77,109,114,115], a battery of stringent methods and criteria
were used to confirm differentiation. Confocal microscopy with 3D reconstruction of
multiple images was used as a first step. This technique clearly demonstrated that a fraction
of CD31+ cells were colocalized with ECs within the vascular structure even up to 8 weeks
after cell injection. To more precisely quantify this transdifferentiation, flow cytometric
analysis using enzymatically digested hindlimb tissues was employed. Quantitative flow
cytometry showed that up to 4% of the ECs in the ischemic tissues were derived from
transplanted mBM- or hPB-CD31+ cells. Fluorescent in situ hybridization of the digested
tissues further confirmed vasculogenic capacity of hPB-CD31+ cells [102]. No previous
studies adopted all of these technologies to prove transdifferentiation of hematopoietic cells.
These data clearly indicate that functional ECs can be derived from directly injected CD31+
cells in the ischemic tissue.
Higher adhesion capacity of CD31+ cells
Studies have shown that engraftment of transplanted neonatal cardiomyocytes is less than
25% within 24 h of MI in animal models [116] and 5% after 1 h postinjection of CD34+
cells in human patients with MI [117]. Our study also demonstrated that most of the cultured
early EPCs injected directly into the myocardium post-MI, disappeared within a week [100].
To enhance therapeutic effects of cell therapy, stable engraftment and survival of
transplanted cells appears to be critical. One recent study suggested an association between
durable engraftment of the transplanted EPCs and maintenance of functional improvement
in experimental diabetic neuropathy [118]. When cultured, early EPCs were intramuscularly
transplanted along the nerve, they engrafted into the diabetic nerve along the vasa nervorum
for more than 12 weeks and improved neural function for more than 8 weeks [118].
Cells that successfully adhere to the extra-cellular matrix have a higher chance of survival
by avoiding anoikis (apoptosis caused by lack of adhesion to extracellular matrix). This
adhesion capacity may play an important role in cell survival, particularly in the ischemic
environment. CD31 was originally cloned as an adhesion molecule between cells [89,119],
and it has been shown to mediate cell-cell adhesion mainly through hemophilic interactions
between CD31-expressing cells [120]. Genome-wide gene expression data showed a high
expression of genes related to adhesion, transmembrane structure, chemokine production
and reception, and extracellular matrix in hPB-CD31+ cells [102]. Cell adhesion assays
further demonstrated that CD31+ cells have a higher adhesion capacity to various
extracellular matrix proteins such as collagen, laminin, vitronectin, and fibronectins than
CD31− cells [101,102]. In fact, the confocal microscopic data and FACS analysis for
digested tissues verified higher engraftment of mBM-CD31+ cells compared with mBM-
CD31− cells in cell transplantation studies with a hindlimb ischemia model. CXCR4/ SDF-1
is well known to mediate cell engraftment and migration. However, the expression of
CXCR4 was not different between CD31+ cells and CD31− cells, suggesting that the higher
engraftment of CD31+ cells does not result from the difference in expression levels of
CXCR4. The higher engraftment of CD31+ cells is likely to augment the angiogenic and
vasculogenic ability of mBM- and hPB-CD31+ cells [101,102]. CD31 is the first marker
used to isolate a BM cell subpopulation that has higher adhesion and engraftment potential.
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Enrichment of hematopoietic stem & progenitor cells in CD31+ cells
Gene expression studies have shown that the levels of hematopoietic stem and progenitor
cell genes were higher in mBM-CD31+ cells and hBM-CD31+ cells than mBM-CD31− cells
and hBM-CD31− cells, respectively (Figure 2) [101], supporting the notion that
hematopoietic stem and progenitor cells are enriched in the CD31+ cells. FACS analysis
confirmed that more than 90% of HSCs, multipotent progenitor cells, common lymphoid
progenitor cells, and common myeloid progenitor cells in mBM express CD31 [101]. In
vitro colony-forming assays and in vivo BM cell transplantation experiments further support
that hematopoietic stem and progenitor cells are almost exclusively included in mBMCD31+
cells [101]. Similarly, in hBM, CD31 was expressed in 99.8% of CD34+CD133+ and 89% of
CD34+CD133−, indicating that HSCs and most HPCs express CD31 [101]. In vitro
hematopoietic colony-forming assays revealed that clonogenic HPCs are enriched in
hPBCD31+ cells [102]. Together, regardless of whether human or mouse, HSCs and HPCs
are almost exclusively present in CD31+ cell fractions.
CD34+ cells are effective for improving ischemic cardiovascular diseases in animal models
[121] and human patients [49,122] with no documented adverse effects. Given that HSCs/
EPCs that are heavily enriched in the CD34+ cell fraction are almost exclusively present in
the CD31+ population, and that HSCs/EPCs have been reported to be vital for therapeutic
neovascularization in ischemic cardiovascular diseases, it is important to address the role of
HSC/EPC versus non-HSC/EPC populations among CD31+ cells in ischemic cardiovascular
repair. One important thing to note is that this non-HSC/EPC population constitutes the
majority of the CD31+ cells. When this population (hBM-CD34−CD31+ cells) was
compared with hBM-CD34+ cells, therapeutic effects between these two groups were
similar in improving mouse limb ischemia, suggesting that non-HSC/EPC populations
among the CD31+ cell fraction also play an important role in therapeutic neovascularization.
Other potentially beneficial effects of CD31+ cells
Given that mBM-, hPB- and hBM-CD31+ cells include immune cells such as B, T and
myeloid cells (Figure 4), it is possible that the CD31+ cells have an immunomodulatory
function to reduce tissue damage and accelerate tissue regeneration. Inflammation is a
double-edged sword that can destroy the tissue or can contribute to the regeneration of
tissue. Since the transplantation of CD31+ cells resulted in the regeneration of ischemic
tissue, it is possible that immune cells that contribute to tissue regeneration [123,124] may
be enriched in CD31+ cells and that tissue-destroying immune cells are relatively depleted in
the CD31+ cell fraction. However, further investigation is required to determine whether the
CD31+ cells have favorable immunomodulatory functions and/or are enriched with tissue-
regenerating immune cells.
Clinical application of CD31+ cells
One major advantage of CD31+ cells over CD34+ or CD133+ cells is their prevalence in
circulating blood. Approximately 30–35% of total MNCs of hPB are CD31+. For instance, if
60 million CD31+ cells are needed for transplantation, only 100 ml of blood is needed
[122,125]. Thus, there is no need to use mobilizing agents, such as G-CSF, for collecting
CD31+ cells [122]. This leads to the reduction in cost of cell therapy, simplification of
treatment procedures and removal of potential adverse effects associated with mobilizing
agents.
Another advantage of CD31+ cells over the cultured EPCs or MSCs is the avoidance of cell
culture. The major limitation of using cultured cells for clinical use is whether or not cells
can be expanded in large scale in a safe manner. Most EPC or MSC expansion protocols
utilize media containing fetal bovine serum. Since fetal bovine serum contains growth
Kim et al. Page 8
Regen Med. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
factors, attachment factors and vital nutrients, it has been one of the most widely used
ingredients for cell culture. However, the use of xenogeneic serum can pose a risk such as
disease transmission, harmful immunizing effects or adverse effects caused by unknown
factors. Potential concerns include viral, prion and zoonose contamination. In fact, antifetal
bovine serum antibodies and inflammatory reactions have been detected and those could
have immunological adverse events and be a factor influencing the therapeutic results [126].
Other potential benefits over uncultured BM-derived MNCs or unfractionated cells is the
removal of unnecessary cells that may induce adverse effects such as calcification [127] or
aggravation of ischemia [128]. We did not observe such adverse effects when we tested the
CD31+ cells in a mouse model of hindlimb ischemia [101,102]. Recent studies suggested
that BM-MNCs [129] or G-CSF-mobilized PB-MNCs [130] are effective in the treatment of
patients with critical limb ischemia. When we compared hBM-MNCs with hBM-CD31+
cells in a mouse model of hindlimb ischemia, the therapeutic efficacy of CD31+ cells was
superior to that of BM-MNCs. Thus, CD31+ cell selection by removing nonangiogenic and
highly inflammatory cells included in the CD31− cell fraction appear to have higher
therapeutic effects and less potential toxicity. If a xeno-derived antibody against CD31 is
used, patients might develop an allergenic reaction caused by the xeno-derived protein.
However, given that many xeno-derived antibodies have been safely used in human patients,
this risk would be minimal.
Future perspective
To identify more angiogenic and/or vasculogenic cells, further experimental investigation is
required. Since CD31+ cells are a heterogeneous cell population that include T and B
lymphocytes and myelomonocytic cells, more angiogenic or vasculogenic cells can be found
by using additional markers. We recently demonstrated that vasculogenic cells are more
abundant in CD14−CD31+ mBM cell populations than in the rest of the population of
CD31+ mBM cells [101]. The addition of other markers will help narrow down the
identification of more angiogenic and vasculogenic cells. Mechanistically, we also need to
determine the role of CD31 itself in the improvement of ischemia. CD31 knockout mice
display a grossly normal phenotype. However, the response of CD31 knockout mice to
pathologic conditions including ischemia or inflammation has not been tested. Moreover,
considering the possibility of compensation for CD31 knockout effects during development,
conditional deletion of CD31 genes may lead to the identification of novel roles of CD31 in
regeneration or repair of ischemic cardiovascular diseases.
As the therapeutic effects of CD31+ cells have been clearly demonstrated in experimental
hindlimb ischemia, clinical trials with CD31+ cells should be the next step. The first target
could be patients with critical limb ischemia or intractable wounds. This cell therapy can be
expanded to the treatment of other ischemic cardiovascular diseases including MI, stroke
and diabetic neuro pathy. Although there are increasing reports that the efficacy of
myocardial repair or regeneration with BM-derived cells may be minimal or modest, studies
with peripheral vascular obstructive disease are very limited and most studies used
unselected BM or PB-MNCs [131]. However, a recent presentation showed that CD34+ cells
are effective in the treatment of critical limb ischemia patients [132]. As such, CD31+ cells
will be a very promising option for critical limb ischemia patients. Another good reason that
CD31+ cells will be effective for treating at least vascular ischemia, is that peripheral tissues
have more room for cell engraftment and present a less hostile environment for cell survival.
A recent diabetic neuropathy study also indicated that the host environment is a more
important factor in determining engraftment and survival [118,133]. Although CD31+ cells
have robust angiogenic and vasculogenic capability, it cannot be ruled out that CD31− cells
can play a significant role in neovascularization. MSCs and pericytes are derived from the
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CD31− cell fraction [101,134] and these mural cells appear to play an important role in late-
stage vessel formation, contributing to vascular maturation [135].
A decade of experience with BM cell therapy for cardiovascular diseases has yielded new
insight into the mechanisms underlying this process. Important discoveries include the major
role of the humoral and paracrine mechanisms in cell therapy, the importance of the host
environment in cell engraftment and therapeutic effects, and the advantages of selected cells.
Based on these new observations and discoveries, it is time to develop next generation adult
cell therapy. Together, cell therapy with CD31+ cells for pulmonary venoocclusive disease
can be a reasonable option to meet this end. Further scientific investigation will require the
discovery of more therapeutically effective cell types, surface markers for genuine EPCs and
appropriate target diseases for cell therapy.
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Executive summary
■ Various subsets of bone marrow (BM)-derived cells were identified,
characterized and attempted cardiovascular regeneration or repair.
■ Early endothelial progenitor cells (EPCs) or circulating angiogenic cells are
isolated in short-term ex vivo culture, and share characteristics of monocytes
and endothelial cells (ECs). Early EPCs have strong humoral effects,
including angiogenic effects, and are effective for repairing ischemic
cardiovascular diseases in animal models.
■ Late EPCs are isolated by relatively long-term ex vivo culture and share
features of mature ECs. The paracrine and therapeutic effects remain to be
determined.
■ Human CD34+ cells are an EPC-enriched population and are effective for the
treatment of ischemic cardiovascular diseases. The cell isolation process
needs BM cell mobilizing reagents and apheresis, and the treatment is costly.
Their transdifferentiation capacity to cardiomyocytes and ECs in vivo is
questionable.
■ Mesenchymal stem cells are derived in ex vivo culture and their
transdifferentiation capacity to cardiomyocytes or ECs in vivo is none too
minimal. MSCs have paracrine and immunomodulatory function.
■ The major mechanisms underlying the therapeutic effects of BM-derived
stem or progenitor cells on cardiovascular diseases are humoral or paracrine
effects.
■ CD31 (Platelet endothelial cell adhesion molecule-1) is a cell adhesion
molecule expressed in endothelial cells, platelets and various hematopoietic
cells, and has been known as a representative marker for ECs. Recent series
of papers have revealed that CD31 can be used as a marker for a BM-derived
mononuclear cell fraction that is highly enriched with angiogenic,
vasculogenic and hematopoietic stem or progenitor cells.
■ Hematopoietic stem and progenitor cells are exclusively included in the BM-
or peripheral blood (PB)-derived CD31+ cell population.
■ BM- and PB-derived CD31+ cells have robust angiogenic capacity and
include genuine vasculogenic cells or true EPCs.
■ BM- and PB-derived CD31+ cells possess high adhesion capability allowing
longer engraftment and retention in ischemic cardiovascular tissues.
■ BM- and PB-derived CD31+ cells are effective for inducing
neovascularization and recovering ischemic tissue injuries.
■ BM- and PB-derived CD31+ cells have advantages over other BM-derived
stem or progenitor cells in therapeutic use as the CD31+ cells are more
abundant than CD34+ or CD133+ cells, and do not require BM mobilizing
reagents and ex vivo culture.
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Figure 1. The schematic structure of CD31
CD31 is a 130-kDa, type I transmembrane glycoprotein, and is a member of the
immunoglobulin gene superfamily.
ITIM: Immunoreceptor tyrosine inhibitory motif.
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Figure 2. Gene expression patterns in CD31+ and CD31− cells
Total RNA was isolated from mBM-CD31+, mBM-CD31−, hBM-CD31+, hBM-CD31−,
human peripheral blood (hPB)-CD31+, hPB-CD31− cells, and hPB-MNC and subjected to
(A & B) microarray and/or (C) real-time reverse transcriptase PCR. (A & B) Gene set
enrichment ana lysis was performed using the microarray data. Gene set enrichment ana
lysis shows angiogenic genes (A) and hematopoietic stem and progenitor cell genes (B) are
globally upregulated in the CD31+ cell fraction; n = 3. (C) The expression patterns of
multiple angiogenic factors in hPB-CD31+ and -CD31− cells. Data are presented as a fold
difference compared with the mononuclear cell group; n = 6.
*p < 0.05; **p < 0.01.
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; hBM: Human bone marrow; mBM:
Mouse bone marrow; MCP: Monocyte chemoattractant protein; MNC: Mononuclear cell;
ns: Not significant; VE-cad: Vascular endothelial cadherin.
(A & B) Reproduced with permission from [101]. (C) Reproduced with permission from
[102].
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Figure 3. Human peripheral blood-CD31+ cells formed vascular tube-like structures during ex
vivo cultivation
The CD31+ cells cultured under endothelial growth media-2 started to form tubular
structures within the cell cluster at culture day 10. The tube grew into a linear structure
stained by lectin (green fluorescence) until day 16, mimicking in vitro vasculogenesis.
Magnification 10×, scale bar = 200 μm.
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Figure 4. Expression of CD31 decreases as the hematopoietic stem and progenitor cells undergo
differentiation
CLP: Common lymphoid progenitor; CMP: Common myeloid progenitor; GMP:
Granulocyte–monocyte progenitor; HSC: Hematopoietic stem cell; LSK: Lin−Sca-1+c-Kit+;
MEP: Megakaryocyte–erythroid progenitor; MPP: Multipotential progenitor; NK: Natural
killer.
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